Search Results
Your search for ,iII matches 9601 pages
Showing 1 - 50Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
A chemotherapy-free front-line regimen of ponatinib plus blinatumomab significantly improved event-free survival compared with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Chiaretti et al reported results from...
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
In the phase III PANKU-Lung01 trial, the bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced nonsquamous non–small cell lung cancer (NSCLC) whose disease had...
Keeping PACE With Surgery: SBRT for Localized Prostate Cancer
An updated efficacy analysis of the international phase III PACE-A trial showed high rates of freedom from biochemical or clinical failure (BCF) with both stereotactic body radiation therapy (SBRT) and radical prostatectomy in patients with localized prostate cancer, with no statistically...
HERON-Lung01: HER3-Directed ADC Prolongs Progression-Free Survival in EGFR-Mutated Advanced NSCLC
In the phase III HERON-Lung01 trial, ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy and showed a manageable safety profile in patients with EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated advanced non–small cell lung cancer (NSCLC),...
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
According to results from the phase III SAFFRON trial, the combination of osimertinib and savolitinib significantly improved progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) with MET...
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
The EGFR and HER3 bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival vs chemotherapy in heavily pretreated Chinese patients with hormone receptor–positive, HER2-negative breast cancer, according to results from the multicenter phase III...
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
First-line pembrolizumab monotherapy significantly improved progression-free survival compared with carboplatin plus paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer, according to an interim analysis of the phase III...
Wake Forest University School of Medicine Names Inaugural Chair of the Department of Cancer Medicine
Antoinette R. Tan, MD, MHSc, FACP, FASCO, has been appointed inaugural Chair of the newly formed Department of Cancer Medicine for the Charlotte, North Carolina campus of Wake Forest University School of Medicine. A clinician-scientist, Dr. Tan is a nationally recognized breast medical oncologist...
Domenica Lorusso, MD, PhD, on Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer
Domenica Lorusso, MD, PhD, of Humanitas University, summarizes findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 study, which showed sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate, provided statistically significant and clinically meaningful improvements in...
Kohei Shitara, MD, on G-HOPE 001: Arcotatug Tavatecan in GI/GEJ Cancer
Kohei Shitara, MD, of the National Cancer Center Hospital East in Kashiwa, Japan, presents findings from the prespecified first interim analysis of the phase III G-HOPE 001 trial, which showed that arcotatug tavatecan, a CLDN18.2-targeted antibody-drug conjugate, demonstrated a statistically...
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
Patients preparing to undergo surgery for pancreatic adenocarcinoma who received stereotactic body radiation therapy (SBRT) appeared to have comparable pathologic and surgical outcomes while reporting better quality of life during treatment than those who received conventionally fractionated...
Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control
A hypofractionated radiotherapy regimen was noninferior to conventional radiotherapy for locoregional control among patients with high-risk breast cancer undergoing postmastectomy radiotherapy with internal mammary node irradiation, according to findings from the phase III HypoMast-IMNI trial...
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
Neoadjuvant niraparib monotherapy produced tumor responses and enabled complete resection in selected patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer who were considered unlikely to achieve complete primary debulking surgery. Dan Liu, MD, and colleagues...
Yelena Y. Janjigian, MD, FASCO, on CLARITY-Gastric 01: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy...
Elizabeth Smyth, MD, on Esophageal/GEJ Cancer: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pembrolizumab in patients with previously untreated locally advanced unresectable esophageal and...
Elizabeth Smyth, MD, on Gastric/GEJ Cancer: Novel CLDN18.2-Targeting ADC
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate arcotatug tavatecan in previously treated patients with gastric or gastroesophageal junction (GEJ)...
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
For patients with relapsed or refractory follicular lymphoma, the timing of progression is one of the factors Peter A. Riedell, MD, considers when choosing the next treatment. A long first remission may support another course of chemoimmunotherapy, but progression within 24 months of starting...
Phase III VOLGA Trial: Durvalumab/Tremelimumab/Enfortumab Vedotin Improves Outcomes in Bladder Cancer
In the phase III VOLGA trial, researchers evaluated the use of perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy....
OptiTROP-Lung06: A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
In patients with advanced PD-L1–negative nonsquamous non–small cell lung cancer (NSCLC) without targetable genomic alterations, first-line treatment with the Trop-2–directed antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab demonstrated a significant progression-free survival...
Selpercatinib, Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
Researchers from Vall d’Hebron University Hospital presented advances in targeted therapies for patients with thyroid cancer during the ESMO Congress 2026. Updated results of the phase III LIBRETTO-531 trial showed durable benefits with selpercatinib compared with existing targeted therapies for...
TALENT: Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Neoadjuvant treatment with the HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki (T-DXd), given alone, with endocrine therapy, or followed by chemotherapy, produced pathologic complete response rates (pCR) in the single digits among patients with hormone receptor (HR)-positive,...
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
Findings from a substudy of the phase III PROTEUS trial provided further support for the use of perioperative apalutamide and androgen-deprivation therapy (ADT) before and after surgery for patients with high-risk localized and locally advanced prostate cancer, according to results presented at the ...
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
In patients with extensive-stage small cell lung cancer (SCLC), tarlatamab-dlle, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than 8 months, more than tripled progression-free survival, and reduced the risk of death by 58%...
James J. Harding, MD, on Advanced Biliary Tract Cancer: Ivonescimab/Chemotherapy vs Durvalumab/Chemotherapy
The phase III HARMONi-GI1 trial is evaluating the efficacy and safety of ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy vs durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer. At the ESMO Congress 2026, invited discussant James J. Harding, MD,...
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Patients with advanced melanoma achieved deep and durable responses after receiving the tumor-infiltrating lymphocyte (TIL) therapy lifileucel alongside the immune checkpoint inhibitor pembrolizumab as a first-line treatment, according to results from a new clinical trial. Approximately two-thirds...
ESMO 2026: Sacituzumab Tirumotecan vs Physician’s Choice of Treatment in Patients With Previously Treated Endometrial Cancer
Sacituzumab tirumotecan may extend both progression-free and overall survival compared with standard chemotherapy in patients with advanced or recurrent endometrial cancer, according to findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 trial presented at the ESMO Congress 2026 (Abstract...
Is Enucleation a Safe Alternative to Pancreatoduodenectomy for Benign or Low-Grade Pancreatic Head Tumors?
A multicenter retrospective cohort study published by Yao et al in JAMA Surgery found that although pancreatic enucleation was associated with a higher rate of clinically relevant postoperative pancreatic fistula than pancreatoduodenectomy, it was linked to fewer major complications, less delayed...
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson...
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC
Patients with previously treated advanced KRAS G12C–mutant non–small cell lung cancer (NSCLC) had improved progression-free and overall survival and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of...
Shannon N. Westin, MD, on Advanced or Recurrent Endometrial Cancer: DUO-E/GOG-3041/ENGOT-EN10
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, reviews interim overall survival and safety results from a randomized phase III study evaluating durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with advanced/recurrent...
Brian M. Slomovitz, MD, on dMMR Advanced or Recurrent Endometrial Cancer: KEYNOTE-C93/GOG-3064/ENGOT-en15
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial carcinoma (Abstract LBA12).
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase III EMT2 trial presented at the European...
Triplet Therapy With Abiraterone Improves Long-Term OS in Metastatic Castration-Sensitive Prostate Cancer
Abiraterone acetate added to androgen-deprivation therapy and docetaxel resulted in a significant overall survival benefit compared with standard-of-care therapy alone in patients with de novo metastatic castration-sensitive prostate cancer, according to long-term findings from the phase III...
High-Risk Melanoma: Personalized mRNA Vaccine Plus Immunotherapy May Benefit Outcomes After Surgery
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract...
Presidential Symposium Highlights in Small Cell Lung Cancer
Three phase III studies in small cell lung cancer (SCLC) were among the notable findings presented during a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer held in Seoul. The studies addressed important questions...
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany...
Patient-Friendly Research Summaries Spotlight Advances in Pancreatic Cancer
The science and practice of translation is about more than moving discoveries from the lab to the clinic. It also helps break down barriers to access so crucial developments in cancer care can reach patients and improve outcomes all over the world. To help you spread the word about these...
ASCO Issues Its First Living Guideline on Systemic Treatment of Recurrent Ovarian Cancer
In June 2026, an ASCO Expert Panel voted to approve ASCO’s first Living Guideline on systemic treatment of ovarian cancer recurrence.1 The continuously updated, evidence-based guideline addresses patients with epithelial ovarian cancer, primary peritoneal carcinoma, and fallopian tube carcinoma,...
Data From Pivotal Trials Lead to Recent Drug Approvals in Colorectal, Breast, RCC, and CLL/SLL Malignancies
In September and October, the U.S. Food and Drug Administration (FDA) released statements regarding the Agency’s approval of a number of oncology drug products across several solid tumors and hematologic malignancies. A summary of these approvals is provided here. Combination Approved in dMMR Colon ...
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
The addition of metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic breast cancer, according to findings from the randomized phase II portion of the NRG-BR002 trial reported by Chmura et al...
Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction
A shorter course of postmastectomy radiation therapy was noninferior to conventional radiation therapy in terms of breast reconstruction complications among women with breast cancer undergoing the procedure, according to findings from the randomized RT CHARM trial reported by Poppe et al in the...
Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
When diffuse large B-cell lymphoma (DLBCL) fails to respond to front-line treatment or the disease later returns, Jeremy S. Abramson, MD, MMSc, wants to know when the disease progressed, if the patient is eligible for chimeric antigen receptor (CAR) T-cell therapy, and whether or not such treatment ...
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair...
Mocertatug Rezetecan Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the...
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
According to findings from the phase III VERIFY trial reported by Kuykendall et al in the Journal of Clinical Oncology, the addition of the hepcidin mimetic rusfertide to standard-of-care therapy significantly improved hematocrit control, reduced the need for phlebotomy, and improved...
Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma
Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD...
ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ...
Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual...
Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma
Nearly half of patients with resected high-risk melanoma treated with adjuvant anti–PD-1 therapy developed chronic immune-related adverse events, and more than one-third still had ongoing toxicity after a median follow-up of more than 5 years. Roma A. Kankaria, MD, and colleagues reported the...
FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC
On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This...
